こんにちは由美子です

Size: px
Start display at page:

Download "こんにちは由美子です"

Transcription

1 Prevalence (proportion) cross sectional study prevalence Time referent: prevalence prevalence Time referent 1985 time referent Risk and Cumulative incidence Risk Cumulative incidence

2 4. I 5 35 Prevalence risk/cumulative incidence point A B (or cumulative incidence: CI) cohort study t-year C = cohort study Framingham Heart Study* cumulative incidence 40/789 = 5% *Framingham cohort study

3 Incidence rate (variable time at entry) (loss to follow-up) person-time person-years 3 incidence rate = 3 /62 person-years 10,100,,,10, =48.4/1,000 person-years rate rate person-time cumulative incidence rate, prevalence rate rate prevalence, cumulative incidence 0 1 (0 100%) Rate (proportion) Incidence rate = ()/(person-time ) 1975 Framingham study General Motors

4 cumulative incidence 1% 5 Harvard School of Public Health CI Loss of follow up bias incidence rate Competing risks cumulative incidence risk Q Q 2 2 Q cumulative incidence incidence rate person-year (mouse year?) competing risks Q incidence rate cumulative incidence cumulative incidence incidence rate competing risks cumulative incidence incidence rate (IR) IR cumulative incidence 4

5 loss of follow-up, competing risks incidence rate 5

6 Incidence rate Cumulative incidence Incidence rate Cumulative incidence IR CI 20 T year C = 1 exp.{- I j T j } Incidence rate I j T j (1983-7) T j 221.1/100,000 PY /100,000 PY 272.1/100,000 PY /100,000 PY 334.8/100,000 PY /100,000 PY 392.3/100,000 PY /100,000 PY 20 year C = 1 exp.{- I j T j } = 5.9% incidence rate t-year C = 1 - exp.{- IT} incidence rate 20-year C = 1 - exp.{ x 5}=1.94% I j T j < 0.1 t year C = I j T j I IT<0.1 t-year C = IT 6

7 7

8 Incidence rate Prevalence Incidence rate (I), Prevalence (P), Duration (D) P = ID / (1 + ID) ID (P < 0.1) Or P/(1 P) = I x D (odds of disease) (prevalence) P/(1 P) P incidence rate P ID (P < 0.1) Prevalence incidence rate duration Incidence rate Duration (D) Prevalence (P) (I) 3/100,000 PY 25 years 75/100,000 40/100,000 PY 1 years 40/100,000 10,000/100,000 PY 3 days 82/100,000 incidence rate incidence rate prevalence 10 I prevalence 8

9 Difference measure Risk difference (RD) = Ce Cu = attributable risk ( ) Ce: cumulative incidence of exposed group, Cu: cumulative incidence of unexposed group -1 < RD < +1 RD C 12/14 7/16 RD = 12/14 7/16 = 42% 42 Rate difference (RD) = Ie Iu Ie: incidence rate of exposed group, Iu: incidence rate of unexposed group - < RD < + RD Person-years 28,010 19,017 IR 41/28,010 15/19,017 RD = 6.71 / 10,000 PY Ratio measure Risk ratio (RR) = Ce / Cu = relative risk RD RR

10 C 12/14 7/16 RR = (12/14) / (7/16) = 1.96 RR 96 RR {RR 0.51} incidence rate incidence rate ratio (RR) = Ie / Iu relative risk Person-years 28,010 19,017 IR 41/28,010 15/19,017 RD = {41 28,010PY}/{15/19,017} = RR RD 0 RR RD PY 1970 vinyl chloride 1, /10 8 PYRD = 1000 x 3.3/10 8 PY - 3.3/10 8 PY= / 10 5 PY RD vinyl chloride vinyl chloride 10

11 Incidence rate / 10 5 person-years RD/ 10 5 PY RR (21-39 cig/day) ,015 1, RD RR RD RR RD effect modification Incidence rate / 10 5 person-years RD/ 10 5 PY RR (21-39 cig/day) RD 10 RR RD effect modification RD RR RD RR 11

12 Attributable risk (rate) & population attributable risk (rate) Attributable risk risk difference (RD) AR = RD = [C exposed C unexposed ] risk difference (attributable risk) Population attributable risk (PAR) PAR = Pr (E) x [C exposed C unexposed ] x 0.42 = (10.5%) Attributable risk percent (AR%) = etiologic fraction, relative excess incidence, attributable proportion AR% = [C exposed C unexposed ]/ C exposed x 100 = [RR - 1]/ RR x 100 = [OR - 1]/ OR x 100 (65-74 ) AR% = (9 1) / 9 x 100 = 89% (65-74 ) AR% = (1.68 1) / 1.68 x 100 = 40% Population attributable risk percent (PAR%) exposure PAR% AR% PAR% = AR% x Pr (E=1/D=1) AR% RR=1.96, APR% = [(1.96 1)/1.96] x 12/19 = /3 12

13 Q incidence prevalence (duration) Q2: prevalence incidence rate Incidence rate incidence rate prevalence Q3: prevalence 100/1000 = 0.10 cumulative incidence / 900 = 0.22 Q Cumulative incidence 1 1 incidence rate cumulative incidence Q5: Person-years = 5 x [( ) / 2] = 100,000 person-years Incidence rate = 270 / 100,000 = 27 / 10,000 Q6 10 person-year

14 / 44 person-months x 12 months = 3.82 /person-year Q7: a. Relative risk (RR) RR = (40/100) / (16/400) = 10 b. AR = RD = (40/100) - (16/400) = 0.36 c. AR% = (C 1 C 0 )/C 1 = ( ) / 0.4 = 0.90 AR% = (RR 1)/RR = (10 1) / 10 = d. PAR = Pr (E) x AR = (100/500) x AR = e. PAR% = Pr(E) x AR% = (40/56) x 0.90 = /3 14

層化

層化 (confounding) Confounding Exposure? Outcome Confounders adjustment (confounders) Not Confounding? 2 exposure 3rd factor 3rd factor NEJM 2000; 342: 1930-6. (adjustment) univariate or crude relative risk

More information

報告書

報告書 1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015

More information

untitled

untitled ... 4...5...6...7...10...11... 12...12...12...13...14...15...15...16...16...17...17...18...18...19...19...19 Hill...20...20...21...21...22...23...24...25... 34...34...35...38-2 - ...41...49...51...51...51...52...53...56...56...57...60...60-3

More information

疫学・生物統計学資料,Rev.4.1

疫学・生物統計学資料,Rev.4.1 2 3 2018 10 13 2 2014 11 17 2 2015 1 25 3 2016 10 2 4 2017 10 9 4.1 2018 2 15 3 1 7 1.1.................................. 7 1.2 (epidemiology).................... 7 1.3......................... 8 1.4 (classification

More information

1 2

1 2 1 2 4 3 5 6 8 7 9 10 12 11 0120-889-376 r 14 13 16 15 0120-0889-24 17 18 19 0120-8740-16 20 22 21 24 23 26 25 28 27 30 29 32 31 34 33 36 35 38 37 40 39 42 41 44 43 46 45 48 47 50 49 52 51 54 53 56 55 58

More information

3 5 6 7 7 8 9 5 7 9 4 5 6 6 7 8 8 8 9 9 3 3 3 3 8 46 4 49 57 43 65 6 7 7 948 97 974 98 99 993 996 998 999 999 4 749 7 77 44 77 55 3 36 5 5 4 48 7 a s d f g h a s d f g h a s d f g h a s d f g h j 83 83

More information

Kaplan-Meierプロットに付加情報を追加するマクロの作成

Kaplan-Meierプロットに付加情報を追加するマクロの作成 Kaplan-Meier 1, 2,3 1 2 3 A SAS macro for extended Kaplan-Meier plots Kengo Nagashima 1, Yasunori Sato 2,3 1 Department of Parmaceutical Technochemistry, Josai University 2 School of Medicine, Chiba University

More information

A Study on Life-Table based on the Death Rate from a Specific Disease by Fumio Nakamura, M. D. Department of Hygiene Okayama University Medical School (Director: Professor Masahiko O. D., M. P. H.) In

More information

2

2 1 2 2005 15 17 21 22 24 25 67 95 3 1 2 3 4 17 4 5 6 7 8 9 PR PR PR 10 11 12 PR 419 844 1,490 950 590 20 12 50 13 12/20 2/28 3/30 14 17 349 666 15 59 6 11 15 17 14 15 15 17 3,525,992 15 59 15 17 18 910

More information

こんにちは由美子です

こんにちは由美子です 1 2 . sum Variable Obs Mean Std. Dev. Min Max ---------+----------------------------------------------------- var1 13.4923077.3545926.05 1.1 3 3 3 0.71 3 x 3 C 3 = 0.3579 2 1 0.71 2 x 0.29 x 3 C 2 = 0.4386

More information

大学等における社会人の受け入れ状況調査

大学等における社会人の受け入れ状況調査 1 1 2 3 4 - - - - - - 6 8 6 2001 30 7 6 3 30 8 6 1 4 3,6,9,12 4 1 1 E 1 3 13 15 4 3 1 ( ) 8. 6 14 8 6 2002 8 8 3 7 60 1 4 4 32 100 12

More information

【知事入れ版】270804_鳥取県人口ビジョン素案

【知事入れ版】270804_鳥取県人口ビジョン素案 7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253

More information

こんにちは由美子です

こんにちは由美子です Sample size power calculation Sample Size Estimation AZTPIAIDS AIDSAZT AIDSPI AIDSRNA AZTPr (S A ) = π A, PIPr (S B ) = π B AIDS (sampling)(inference) π A, π B π A - π B = 0.20 PI 20 20AZT, PI 10 6 8 HIV-RNA

More information

Ishi

Ishi Ishi HPhttp: // www.mof.go.jp / jouhou / syuzei / siryou /.htm.. or ERTA, TRA ERTA Economic Recovery Tax Act TRA Tax Reform Act Mroz Triest Lindsey Burtless Navrati Lindsey Burtless Navrati CPS Current

More information

200608094-101

200608094-101 94 A O D 1 A 1 A A 1 AO 1 95 A OA 1 a r A A 1 r A R 1 A R 1 A R 1 a a A OA R 1 96 F AO 1 A O 1 A 1 A O 1 A 1 O A 1 97 b O AO 1 O AO 1 A 1 A OA 1 AO 1 AA 1 98 A AO 1 A AO 1 b b 1 b b B B A 1 Q 1 rr 1 99

More information

Chapter 1 Epidemiological Terminology

Chapter 1 Epidemiological Terminology Appendix Real examples of statistical analysis 検定 偶然を超えた差なら有意差という P

More information

Ⅰ. Statistics Concerning Health Birthweight (1) Birthweight by year (2) Mean birthweight by prefecture, 2007-1997 (3) Percentage of births under 2,500g by prefecture, 2007-1997 Sex Ratio (4) Sex ratio

More information

2 21 211,,, (Hz), AM (1MHz), 300m, 24 (245GHz), 12cm, 212 (electromagnetic fields), (electromagnetic radiations) (NIR),X,,,, RF, ELF,,, 22 221,, 2005

2 21 211,,, (Hz), AM (1MHz), 300m, 24 (245GHz), 12cm, 212 (electromagnetic fields), (electromagnetic radiations) (NIR),X,,,, RF, ELF,,, 22 221,, 2005 1 2003 6 7500 2 1 1 1 WHO, IARC, 2004 2 1973 1993 16 1997 SAR 2002 6, SAR 2W/kg, WHO ICNIRP 2 21 211,,, (Hz), AM (1MHz), 300m, 24 (245GHz), 12cm, 212 (electromagnetic fields), (electromagnetic radiations)

More information

Q-...g.L..465

Q-...g.L..465 20 8 H e a r t F u l l I n f o r m a t i o n No.465 2 Heart Full Information 3 3 27 6 0 22 3 Heart Full Information 29 42 79 50 29 20 30 5 9 5 5 22 96 86 22 4 Heart Full Information 53 24 5 Heart Full

More information

1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):

More information

untitled

untitled 146,650 168,577 116,665 122,915 22,420 23,100 7,564 22,562 140,317 166,252 133,581 158,677 186 376 204 257 5,594 6,167 750 775 6,333 2,325 298 88 5,358 756 1,273 1,657 - - 23,905 23,923 1,749 489 1,309

More information

- 1 - - 0.5%5 10 10 5 10 1 5 1

- 1 - - 0.5%5 10 10 5 10 1 5 1 - - - 1 - - 0.5%5 10 10 5 10 1 5 1 - 2 - - - - A B A A A B A B B A - 3 - - 100 100 100 - A) ( ) B) A) A B A B 110 A B 13 - 4 - A) 36 - - - 5 - - 1 - 6-1 - 7 - - 8 - Q.15 0% 10% 20% 30% 40% 50% 60% 70%

More information

52-2.indb

52-2.indb Jpn. J. Health Phys., 52 (2) 55 60 (2017) DOI: 10.5453/jhps.52.55 * 1 * 2 * 2 * 3 * 3 2016 10 28 2017 3 8 Enhancement of Knowledge on Radiation Risk Yukihiko KASAI,* 1 Hiromi KUDO,* 2 Masahiro HOSODA,*

More information

取扱説明書

取扱説明書 ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22

More information

17 17 17 17 11 21 28 1 24 12 36 2,000 2 22 11 3.67 3.38 22 2.97 21 10 1.7 1.12 22 10 13 2.75 11 10 15 24 10 12 14 3 17 17 2006 4 17 10 24 12 17 5 15 17 17 11 40 6 17 40 17 11 7 24 17 24 17 8 40 17 17 9

More information

untitled

untitled ,337 37 35 0,349,09 35 55 988 3 0 0 3,387 7 90 0,369,46 5 57 5 0 90 38 8,369 3 4 5 6 7 8 9 0 3 4 5 6 7 8 9 0 3 4 5 6 8 9 30 3 3 5,400 7,00 9,000 0,800,600 4,400 6,00 8,000 9,800,600 3,400 5,00 7,000 8,800

More information

,877 61,524 33, ,292, ,653 57,601 95,188 2,416 1,767,

,877 61,524 33, ,292, ,653 57,601 95,188 2,416 1,767, 02 02 02 180,771 07 02 01 1,377 07 02 02 1,051,703 07 02 05 220,099 07 03 01 926,597 08 02 04 1,877,566 08 04 02 2,973,603 08 05 03 672,950 10 06 03 778,433 10 06 04 735,789 10 06 06 225,392 10 06 07 365,442

More information

PowerPoint Presentation

PowerPoint Presentation 2 9/ 3 3 9/ 9 4 5 , PR () 6 ,,, (11) 7 PR 8 9 10 11 TEL. 106 8/131512/291/3 TEL. 107 12/291/3 12 http://www.f-turn.jp/ 13 21 4 21 14 200910 U 200911 U 200911 20102 15 20102 PR 20103 20103 16 20103 20104

More information

p01.qxd

p01.qxd 2 s 1 1 2 6 2 POINT 23 23 32 15 3 4 s 1 3 2 4 6 2 7003800 1600 1200 45 5 3 11 POINT 2 7003800 7 11 7003800 8 12 9 10 POINT 2003 5 s 45700 3800 5 6 s3 1 POINT POINT 45 2700 3800 7 s 5 8 s3 1 POINT POINT

More information

ワタベウェディング株式会社

ワタベウェディング株式会社 1 2 3 4 140,000 100,000 60,000 20,000 0 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 5 6 71 2 13 14 7 8 9 10 11 12 1 2 2 point 1 point 2 1 1 3 point 3 4 4 5 6 point 4 point 5 point 6 13 14 15 16 point 17

More information

untitled

untitled 1 2 3 4 5 6 7 Point 60,000 50,000 40,000 30,000 20,000 10,000 0 29,979 41,972 31,726 45,468 35,837 37,251 24,000 20,000 16,000 12,000 8,000 4,000 0 16,795 22,071 20,378 14 13 12 11 10 0 12.19 12.43 12.40

More information

ヤフー株式会社 株主通信VOL.16

ヤフー株式会社 株主通信VOL.16 01 260,602264,402 122,795125,595 64,84366,493 107110 120,260123,060 0 500 300 400 200 100 700 600 800 39.8% 23.7% 36.6% 26.6% 21.1% 52.4% 545 700 0 50 200 150 100 250 300 350 312 276 151 171 02 03 04 POINT

More information

-- 0 500 1000 1500 2000 2500 3000 () 0% 20% 40% 60%23 47.5% 16.0% 26.8% 27.6% 10,000 -- 350 322 300 286 250 200 150 100 50 0 20 21 22 23 24 25 26 27 28 29 -- ) 300 280 260 240 163,558 165,000 160,000

More information

株主通信:第18期 中間

株主通信:第18期 中間 19 01 02 03 04 290,826 342,459 1,250,678 276,387 601,695 2,128,760 31,096 114,946 193,064 45,455 18,478 10,590 199,810 22,785 2,494 3,400,763 284,979 319,372 1,197,774 422,502 513,081 2,133,357 25,023

More information

1003shinseihin.pdf

1003shinseihin.pdf 1 1 1 2 2 3 4 4 P.14 2 P.5 3 P.620 6 7 8 9 10 11 13 14 18 20 00 P.21 1 1 2 3 4 5 2 6 P7 P14 P13 P11 P14 P13 P11 3 P13 7 8 9 10 Point! Point! 11 12 13 14 Point! Point! 15 16 17 18 19 Point! Point! 20 21

More information

株主通信 第16 期 報告書

株主通信 第16 期 報告書 10 15 01 02 1 2 3 03 04 4 05 06 5 153,476 232,822 6,962 19,799 133,362 276,221 344,360 440,112 412,477 846,445 164,935 422,265 1,433,645 26,694 336,206 935,497 352,675 451,321 1,739,493 30,593 48,894 153,612

More information

Microsoft Word - StatsDirectMA Web ver. 2.0.doc

Microsoft Word - StatsDirectMA Web ver. 2.0.doc Web version. 2.0 15 May 2006 StatsDirect ver. 2.0 15 May 2006 2 2 2 Meta-Analysis for Beginners by using the StatsDirect ver. 2.0 15 May 2006 Yukari KAMIJIMA 1), Ataru IGARASHI 2), Kiichiro TSUTANI 2)

More information

2 ( ) i

2 ( ) i 25 Study on Rating System in Multi-player Games with Imperfect Information 1165069 2014 2 28 2 ( ) i ii Abstract Study on Rating System in Multi-player Games with Imperfect Information Shigehiko MORITA

More information

人 々ばかりでなく 被 曝 時 年 齢 10~19 歳 のグループにおいても 減 少 しつつあるということである 20 歳 以

人 々ばかりでなく 被 曝 時 年 齢 10~19 歳 のグループにおいても 減 少 しつつあるということである 20 歳 以 O~O~O~O~O~O~O~OOOO~O~O~OOOO~OOOO~OO O~~~O~O~O~O~OOOO~O~O~O~OOOOO~~ 人 々ばかりでなく 被 曝 時 年 齢 10~19 歳 のグループにおいても 減 少 しつつあるということである 20 歳 以 .~ 1) Y. Shimizu, H. Kato and W. J. Schull: Life span study report

More information

1 2 3 4 10 5 30 87 50 20 3 7 2 2 6 3 70 7 5 10 20 20 30 14 5 1,000 24 112 2 3 1 8 110 9 JR 10 110 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 25 30 31 32 25 A 33 B C D E F G PR PR or 34 35

More information

untitled

untitled 186 17 100160250 1 10.1 55 2 18.5 6.9 100 38 17 3.2 17 8.4 45 3.9 53 1.6 22 7.3 100 2.3 31 3.4 47 OR OR 3 1.20.76 63.4 2.16 4 38,937101,118 17 17 17 5 1,765 1,424 854 794 108 839 628 173 389 339 57 6 18613

More information

untitled

untitled 1. 3 14 2. 1 12 9 7.1 3. 5 10 17 8 5500 4. 6 11 5. 1 12 101977 1 21 45.31982.9.4 79.71996 / 1997 89.21983 41.01902 6. 7 5 10 2004 30 16.8 37.5 3.3 2004 10.0 7.5 37.0 2004 8. 2 7 9. 6 11 46 37 25 55 10.

More information

@08460025ヨコ/伊東 217号

@08460025ヨコ/伊東 217号 A B B A B A B A B stratification inequality Marmot, Smith, Why are the Japanese living longer?, British Medical Journal, 1989 Kondo, Kawachi, Subramanian, Takeda, Yamagata Do social comparisons

More information

立命館

立命館 SPORT AND HEALTH SCIENCE Research Study Report 2011 01 02 03 Sport and Health Science 04 PICK UP VOICE 05 Sport and Health Science 06 PICK UP VOICE 07 Sport and Health Science PICK UP VOICE 08 09 Sport

More information

B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B

B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B 10 1 575 10 12 586 B B 10 1 575 10 2 576 B B 10 4 578 10 5 579 10 3 577 B 10 6 580 B B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B 11 1 587 11 12 598 B B 11 1 587 11 2 588 11 3 589

More information

(資料2)第7回資料その1(ヒアリング概要)

(資料2)第7回資料その1(ヒアリング概要) 2 3 4 5 6 7 8 9 10 11 12 13 1 1 1 1 5 1 6 533 4 505 722 13 3325 475 1 2 3 13 10 31 1 1 1 (1) 1 (2) 2 (3) 3 (4) 4 5 5 6 7 8 8 8 9 11 11 12 13 14 15 16 19 (1) (2) (3) (1) (5 ) 1 (10 ) ( ) (2) 2 4 (3) 3 3,100

More information

IT 180 181 1) 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 (a) (b) (c) (d) (e) (f) (a) (a) (b) 214 215 216 (a) (a) (a)

More information

-------------------------- ----------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------

More information

<4D F736F F D DEC8BC A95BD90AC E A982BA81698AB A B B4790DF90AB8EBE8AB FC89408A4F816A82CC93AE8CFC82C98AD682B782E9838C837C815B D

<4D F736F F D DEC8BC A95BD90AC E A982BA81698AB A B B4790DF90AB8EBE8AB FC89408A4F816A82CC93AE8CFC82C98AD682B782E9838C837C815B D 27 29 2 IT 1,234 1,447 2,130 1,200 3,043 4 3 75 75 70-74 -10 J00 J101 J110 J111 J118 J300 J302-304 J301 26,475,118 155,290,311 1,234 14,472,130 75,784,748 12,003,043 79,505,563 1 1.00% 0.62% 1.31% 9 12

More information

, , ,210 9, ,

, , ,210 9, , 2006 5 642 7 2,671 35 732 1,727 602 489 386 74 373 533 305 1,210 9,786 2004 1,024 43.7 16.4 2004 978.6 40.2 2003 1 2006 5 1997 1998 1999 774 3,492 11 2,603 35 843 5,118 1,686 476 358 2000 738 3,534 11

More information